DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Residual Renal Function Preservation in Peritoneal Dialysis Patients

Information source: Second Xiangya Hospital of Central South University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Renal Disease

Intervention: Losartan (Drug); spirolactone (Drug); blank control (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Second Xiangya Hospital of Central South University

Overall contact:
Hong Liu, MD,phD, Phone: 86-0731-85292057, Email: liuh0618@163.com

Summary

Aldosterone blockade is useful in preserving residual renal function in patients on PD. The long term efficacy of dual blockade of the RAAS is better than monotherapy.

Clinical Details

Official title: The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: residual renal function of peritoneal dialysis patients

Secondary outcome: peritoneal membrane function

Detailed description: Residual renal function has been proven to contribute to improved survival and quality of life of dialysis patients. It is now recognized as an important factor in the prognosis of PD. The RAAS system is involved in the development of renal diseases. Angiotensin II and aldosterone are vital in this process. The beneficial effect of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on residual renal function has been demonstrated in peritoneal dialysis patients. Unfortunately, neither ACE inhibition nor angiotensin receptor blocker fully supprsses aldosterone production. Now much focus has been placed on aldosterone antagonist.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who having been on PD continuously for one month, urine volume>600 ml/d,

residual renal function>2ml/min/1. 73m2, blood pressure>120/70mmHg, serum potassium levels<5. 5mmol/l, stable clinical condition. Exclusion Criteria:

- Patients with infectious systemic disease, peritonitis during the preceding 1 month,

who had taken ACEI/ARBs in the 3 preceding months, spirolactone in the 2 preceding weeks, intolerance to ACEI/ARBs, CHF, MI, malignant hypertension and stroke within the preceding 6 months.

Locations and Contacts

Hong Liu, MD,phD, Phone: 86-0731-85292057, Email: liuh0618@163.com

Changsha, Hunan 410000, China; Recruiting
Hong Liu, MD,phD, Phone: 86-0731-85292057, Email: liuh0618@163.com
Hong Liu, MD,phD, Principal Investigator
Additional Information

Starting date: November 2013
Last updated: July 31, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017